Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized Verapamil in COPD Exacerbation
NCT07866989Completed
- Sponsor
- Ain Shams University
- Start
- Apr 2023
- Primary completion
- Mar 2024
- Countries
- 1
01
Overview
Randomised trial of verapamil in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Ain Shams University. Primary endpoints: Peripheral Oxygen Saturation at Day 3, Arterial Oxygen Partial Pressure at Day 3 and 3 more. Started Apr 2023; status: completed.
02
Drugs
verapamil
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07866989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07866989.